Larvol Delta - Mateon-Therapeutics-Selects-IQVIA-for-its-Randomized-Controlled-MultiCenter-Clinical-Study-to-Test-OT101-as-a-Treatment-for-COVID19-Patients

trabedersen (OT-101) - Autotelic, Mateon Therapeutics

https://www.globenewswire.com/news-release/2020/06/23/2051868/0/en/Mateon-Therapeutics-Selects-IQVIA-for-its-Randomized-Controlled-Multi-Center-Clinical-Study-to-Test-OT-101-as-a-Treatment-for-COVID-19-Patients.html

Jun 23, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next